Melanoma Trial, Recruiting NCT07511933 Sponsor: The Netherlands Cancer Institute Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT07511933
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing and able to sign a consent form agreeing to take part in the trial
  • You must be 18 years old or older
  • You must be well enough to carry out some daily activities (a general health score will be assessed)
  • You must have a measurable brain lesion of at least 10mm in size
  • You may qualify for one of several groups: people newly diagnosed with brain tumours that have spread from lung cancer, melanoma (skin cancer), or breast cancer; people who have developed radiation damage in the brain after previous targeted radiation treatment (more than 9 months ago) for spread from lung cancer, melanoma, or breast cancer; or people whose brain scan results are unclear — where doctors are unsure whether a brain lesion is radiation damage or a returning tumour — from lung cancer, melanoma, or breast cancer

Who may not be able to join:

  • You cannot take part if you have a known allergy to the scan substance called Ga-68 PSMA
  • You cannot take part if you have had an epileptic seizure within the last 7 days before the scan
  • You cannot take part if your life expectancy is less than 3 months
  • You cannot take part if you have been diagnosed with prostate cancer
  • You cannot take part if you are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dieta Brandsma, MD, PhD, Antoni van Leeuwenhoek Ziekenhuis

Phone: 0031205129111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Netherlands Cancer Institute
Registry
ClinicalTrials.gov
Start date
24 December 2019
Est. completion
1 January 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Tracer Uptake (SUVpeak) on PSMA PET/CT in Brain Lesions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov